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Abstract
Background: Mild retinopathy (microaneurysms or dot-blot hemorrhages) is observed in persons without diabetes or
hypertension and may reflect microvascular disease in other organs. We conducted a genome-wide association study
(GWAS) of mild retinopathy in persons without diabetes.
Methods: A working group agreed on phenotype harmonization, covariate selection and analytic plans for within-cohort
GWAS. An inverse-variance weighted fixed effects meta-analysis was performed with GWAS results from six cohorts of
19,411 Caucasians. The primary analysis included individuals without diabetes and secondary analyses were stratified by
hypertension status. We also singled out the results from single nucleotide polymorphisms (SNPs) previously shown to be
associated with diabetes and hypertension, the two most common causes of retinopathy.
Results: No SNPs reached genome-wide significance in the primary analysis or the secondary analysis of participants with
hypertension. SNP, rs12155400, in the histone deacetylase 9 gene (HDAC9) on chromosome 7, was associated with
retinopathy in analysis of participants without hypertension, 21.360.23 (beta 6 standard error), p = 6.661029. Evidence
suggests this was a false positive finding. The minor allele frequency was low (,2%), the quality of the imputation was
moderate (r2,0.7), and no other common variants in the HDAC9 gene were associated with the outcome. SNPs found to be
associated with diabetes and hypertension in other GWAS were not associated with retinopathy in persons without
diabetes or in subgroups with or without hypertension.
Conclusions: This GWAS of retinopathy in individuals without diabetes showed little evidence of genetic associations.
Further studies are needed to identify genes associated with these signs in order to help unravel novel pathways and
determinants of microvascular diseases.
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Introduction
Mild retinopathy, defined as the presence of isolated microan-
eurysms or dot-blot hemorrhages, is frequently observed in the
general non-diabetic population. Several population studies report
these signs are found in 5 to 15% of adults without diabetes
[1,2,3]. These retinopathy lesions represent a disruption of the
blood–retinal barrier that results from increased arteriolar tone,
vasospasm, media hyperplasia, intimal thickening and degenera-
tion of vascular smooth muscle with or without endothelial cell
necrosis [3]. In addition, these clinical findings are typically
transitory in nature making them difficult to study [2].
The etiology of mild retinopathy in individuals without diabetes
remains unclear [4]. Risk factors identified in individuals without
diabetes include older age, hypertension, impaired glucose
tolerance, dyslipidemia, obesity and elevated levels of inflamma-
tory markers. Of these, hypertension is the major risk factor
[5,6,7,8,9]. In normotensive individuals, few risk factors have been
consistently identified.
Importantly, mild retinopathy signs have been suggested to
reflect microvascular disease in other end organs. For example,
studies have shown mild retinopathy signs are associated with
renal dysfunction [10,11,12], incident hypertension [1], clinical
stroke [13,14,15,16,17], congestive heart failure [18], and
cardiovascular mortality [19,20]. Mild retinopathy may also signal
subsequent risk of clinical diabetes for individuals who do not
currently have diabetes but have a family history of diabetes [21].
To date, no genetic studies of mild retinopathy have been
conducted in a population without diabetes. In an attempt to
identify biological pathways involved in the pathogenesis of these
signs, we conducted a genome-wide association study (GWAS) to
examine the association between ,2.5 million single nucleotide
polymorphisms (SNPs) and the presence of isolated microaneu-
rysms or dot-blot hemorrhages. This was done in six community-
based cohorts comprising 19,411 individuals of European ances-
try, followed by a meta-analysis of GWAS results. The primary
analysis was restricted to individuals without diabetes and
secondary analyses were stratified by hypertension status. No
European cohorts were available for replication so we examined
the SNP and locus transferability of genome-wide significant
results in a cohort of Singapore Indian Asians and an African
American cohort. We also investigated the association of these loci
with other diseases that may share a similar microvascular
etiology, including kidney disease, in cohorts of European
ancestry. Finally, we looked at SNPs identified in previous GWAS
of diabetes and hypertension (the two most common causes of
retinopathy [22,23]) to determine if they were associated with
retinopathy in a normotensive population thought to be free of
diabetes.
Methods
Ethics Statement
Each cohort secured approval from their respective institutional
review boards, and all participants provided written informed
consent in accordance with the Declaration of Helsinki.
Study Population
The study population was comprised of individuals from six
studies across Australia, Europe and the United States. Partici-
pants of European ancestry came from the Cohorts for Heart and
Aging Research in Genetic Epidemiology (CHARGE) Consortium
[24] {the Age, Gene/Environment Susceptibility (AGES)–Reykja-
vik Study [25], the Atherosclerosis Risk in Communities (ARIC)
Study [26], the Cardiovascular Health Study (CHS) [27], and the
Rotterdam Study (RS) [28]}, the Blue Mountain Eye Study [29]
(BMES) and the Multi-Ethnic Study of Atherosclerosis (MESA)
[30].
All participating studies approved guidelines for collaboration,
and a working group agreed on phenotype harmonization,
covariate selection and analytic plans for within-study analyses
and meta-analyses of results. Details of each participating study are
provided in the Supplementary Material including sample
selection, retinopathy grading, genotyping platform, imputation
algorithm, and quality control procedures used by each study.
The Reykjavik Study is a population study with a random
sample of 30,794 residents assembled in 1967 to study cardiovas-
cular disease and its risk factors among those born between 1907
and 1935. The AGES is a prospective study of 5,764 surviving
members, aged 66 years and older recruited from 2002–2006 [25].
It was designed to examine genetic susceptibility and environ-
mental interactions as risk factors for disease and disability in old
age.
The ARIC study is a population-based prospective cohort study
of cardiovascular disease and its risk factors [26]. ARIC included
15,792 individuals aged 45 to 64 years at baseline (1987–1989),
selected by probability sampling from four US communities.
The BMES is a population-based cohort study of vision and
common eye diseases in an urban older population comprising two
postcode areas in the Blue Mountains region, west of Sydney,
Australia [29]. The original cohort (1992–1994) included 3,654
participants, of those, 2,335 participants were examined at the
five-year follow up exam and 1,952 at the ten-year exam.
The CHS is a population-based cohort study of risk factors for
cardiovascular disease in adults 65 years of age or older conducted
at four field centers [27]. The original cohort of predominantly
European ancestry consisted of 5,201 participants recruited in
1989–1990 from random samples of Medicare lists. An additional
687 African-Americans were enrolled in 1992–1993.
MESA is a prospective study of 6,814 adults aged 45–84 years
with no history of clinical cardiovascular disease at the baseline
exam (July 2000–July 2002) [30]. Each site recruited equal
numbers of men and women with site-specific racial and ethnic
proportions. Participants defined themselves as European, African,
Hispanic, or Chinese Americans. Only subjects of European
ancestry were used in the discovery phase of this study.
The RS is a prospective population-based cohort study
comprising 7,983 participants aged 55 years or older from
Ommoord, a district of Rotterdam, the Netherlands. It was
designed to investigate the incidence and progression of diseases in
the elderly and the original cohort was identified between 1990
and 1993 [28].
Retinopathy
Retinopathy was defined as the presence of microaneurysms or
dot-blot hemorrhages. Individuals with diabetes were excluded.
We also excluded individuals with secondary causes of retinopathy
(e.g. branch or central retinal vein occlusions, late age-related
macular degeneration) and other retinopathy phenotypes includ-
ing exudates without microaneurysms or dot-blot hemorrhages
and pre-retinal or vitreous hemorrhages.
Fundus photographs were graded using site-specific standard-
ized protocols (Supplemental Material). Not all sites took pictures
with multiple fields of view through dilated pupils in both eyes.
Some sites took photographs through undilated pupils (ARIC,
CHS, MESA), some sites were limited to photographs using 1 field
of view (ARIC, CHS, RS) and one site (CHS) did not take
photographs of both eyes.
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Diabetes and Hypertension
Diabetes was defined by self-report or fasting blood glucose
$126 mg/dL [7.0 mmol/L]. In Rotterdam, fasting glucose was
not available at baseline so participants were excluded if random
glucose was .198 mg/dL [11.0 mmol/L]. Hypertension was
defined as current use of blood pressure medication or systolic/
diastolic blood pressure $140/90 mm Hg.
Genotyping
Different genotyping platforms were used by the individual
studies prior to formation of collaborative phenotype working
groups. The AGES and CHS used the Illumina HumanCNV370-
Duo. The ARIC and MESA studies used the Affymetrix
GeneChip SNP Array 6.0. The BMES used the Illumina
Human670Quadv1 custom chip. The RS used the Illumina
Infinium HumanHap550-chip v3.0. All of the cohorts imputed to
about 2.5 million SNPs using the HapMap Centre d’Etude du
Polymorphisme Humain collection samples from Utah (CEU)
reference panel [31] after quality control analyses, (Supplementary
Material).
Statistical Analysis
In participants without diabetes, a GWAS of mild retinopathy
including microaneurysms and dot-blot hemorrhages was con-
ducted by each of the six cohorts described above. Logistic
regression was performed using an additive genetic model with a
1-degree of freedom test of trend relating the presence of
retinopathy to genotype dosage (0–2 copies of the coded allele)
and adjusting for age, sex and systolic blood pressure. For
individuals currently taking medication to control blood pressure,
10 mm of Hg was added to the measured systolic blood pressure
based on methods established for previous GWAS of hypertension
and blood pressure [32]. This was chosen as a more parsimonious
method rather than adjusting separately for both systolic blood
pressure and current use of medication to treat hypertension.
ARIC and CHS also adjusted for clinic site, BMES adjusted for
four multi-dimensional scaling dimensions and MESA adjusted for
population structure using 10 principal components. Regression
coefficients and their standard errors were determined using the
ProbABEL program (http://mga.bionet.nsc.ru/˜ yurii/ABEL/)
[33] in AGES, ARIC, BMES and RS. R software (http://www.
r-project.org) was used in CHS and SNPTEST v2 [34,35] was
used in MESA.
An inverse-variance weighted fixed effects meta-analysis of the
beta coefficients and standard errors from each site was performed
using METAL software (http://www.sph.umich.edu/csg/
abecasis/Metal/index.html). The fixed-effects analysis provides a
good approximation of the estimates we would get from a
Table 1. Subject characteristics by study site.
Subject Characteristic AGES ARIC BMES CHS MESA RS
Sample Size* 2,451 7,116 2,237 966 2,059 4,582
HTN 1,941 2,614 1,656 494 728 1,433
No HTN 510 4,502 581 472 1,331 3,149
Age (years){ 76.065.4 60.165.6 66.869.1 78.364.1 63.9610.1 67.968.3
HTN 76.565.4 61.565.6 67.968.8 78.564.2 67.769.6 69.968.3
No HTN 74.264.9 59.365.5 63.869.0 78.163.9 61.769.7 67.168.1
Body Mass Index (kg/m2){ 26.964.3 27.564.9 27.564.7 26.364.1 27.564.9 26.263.6
HTN 27.164.4 28.865.3 28.064.8 26.964.4 28.764.9 27.263.7
No HTN 26.064.0 26.864.5 26.163.9 25.663.5 26.864.7 25.863.5
Systolic Blood Pressure (mm Hg){ 141.7619.7 121.9617.9 146.4621.5 134.5620.0 120.2618.9 138.0621.8
HTN 145.9619.6 133.7619.8 154.6618.4 137.1620.7 132.7620.4 155.6622.5
No HTN 125.669.3 115.0612.2 123.369.5 131.8618.9 112.7613.1 130.0616.1
Diastolic Blood Pressure (mm Hg){ 74.269.5 70.869.9 84.7610.2 68.5610.8 68.869.6 73.8611.3
HTN 75.069.9 74.4611.0 87.369.5 68.6610.0 71.7610.2 80.0611.9
No HTN 71.367.2 68.668.49 77.268.1 68.4611.5 67.068.6 71.069.8
Females (%) 58.9 54.3 56.6 64.7 52.0 58.6
HTN 59.8 52.8 57.7 65.2 50.4 63.1
No HTN 55.7 55.1 53.5 64.2 52.7 56.5
Current Smokers (%) 12.9 17.4 9.8 5.6 17.1 23.3
HTN 12.1 14.8 8.3 4.9 10.7 19.2
No HTN 15.9 18.9 14.1 6.4 20.8 25.1
Fasting Glucose (mg/dl) 99.169.0 98.4610.0 98.5630.3 91.569.4 91.169.4 113.4623.4{
HTN 99.669.1 100.0610.3 99.9630.7 92.769.5 92.869.8 117.0623.4{
No HTN 97.368.6 97.469.7 94.7628.7 90.269.1 90.068.9 111.6623.4{
*Sample size of cohort used for primary analysis.
{Presented as mean (standard deviation).
{Random glucose. HTN: Current use of blood pressure medication or systolic/diastolic blood pressure $140/90. AGES: Age, Gene/Environment Susceptibility-Reykjavik
Study. ARIC: Atherosclerosis Risk in Communities study. BMES: Blue Mountains Eye Study. CHS: Cardiovascular Health Study. MESA: Multi-Ethnic Study of Atherosclerosis.
RS: Rotterdam Study.
doi:10.1371/journal.pone.0054232.t001
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combined analysis in which we adjusted for cohort effects. While a
random-effects analysis adjusts for heterogeneity between studies,
there were too few cohorts available in this study to have power to
measure heterogeneity across cohorts. Strand information was
available from all the cohorts and all results were synchronized to
the forward strand. The level of genome-wide significance was set
at p,561028, corresponding to a family-wise p-value of 0.05 after
Bonferroni correction for one million independent tests. To
account for possible residual population structure or other
confounding factors, genomic control [36] was applied to each
cohort before meta-analysis. This entailed multiplying the standard
error of the SNP regression coefficient by the square root of the
estimated genomic control inflation factor for that cohort.
In the secondary analyses, participants were stratified by
hypertension status, defined above. Adjustments for the stratified
analyses were the same as those used for the primary analysis
except no adjustment was included for systolic blood pressure in
individuals without hypertension and systolic blood pressure was
replaced by an indicator variable for treatment of hypertension
(yes/no) in the analyses of individuals with hypertension.
We also examined the SNP and locus transferability of our
findings to cohorts of other ethnicities including Singapore Asian
Indians from the Singapore Indian Eye Study (SINDI) [37] and
African Americans in the MESA cohort. First we looked at the
SNP transferability to the SINDI and MESA cohorts using a
significance level of 0.05. Second we looked at the locus
transferability by examining all the SNPs in the gene of interest.
For those tests we determined the number of tag SNPs required to
cover the gene of interest for each ethnicity using the Genome
Variation Server (http://gvs.gs.washington.edu/GVS). In all cases
we excluded HapMap 3 and selected the following additional
parameters; minor allele frequency of .0.01, r2 threshold = 0.5
and no monomorphic sites. Combined samples and combined
variations of the Han Chinese of Beijing China (HCT)/Japanese
in Tokyo, Japan (JPT) populations were used for the Singapore
cohort and the Yoruba in Ibadan, Nigeria (YRI) population for the
African American cohort from MESA. The level of significance
was set at the Bonferroni-corrected p-value based on the number
of tag SNPs for each population at each gene tested, p,4.961024
for Singapore Asian Indians and p,1.761024 in African
Americans.
In addition, we investigated the association of these loci with
chronic kidney disease and cardiovascular disease. This was
accomplished by performing in silico look-ups in the Chronic
Kidney Disease Genetics (CKDGen) consortium [38] (chronic
kidney disease, microalbuminuria, urinary albumin/creatinine
Table 2. Distribution of retinopathy lesions.
Cohort n Any Retinopathy* (%) Microaneurysms (%) Dot-blot Hemorrhages (%)
AGES
All subjects 2451 11.4 6.3 5.9
HTN 1941 12.0 6.4 6.3
No HTN 510 9.4 5.7 4.1
ARIC
All subjects 7,116 2.3 1.2 1.3
HTN 2,614 2.8 1.5 1.7
No HTN 4,502 2.1 1.0 1.1
BMES
All subjects 2,237 8.4 NA NA
HTN 1,656 9.2 NA NA
No HTN 581 6.4 NA NA
CHS
All subjects 966 5.6 2.8 3.8
HTN 494 6.9 3.9 4.5
No HTN 472 4.2 1.7 3.2
MESA
All subjects 2,059 7.0 4.2 3.0
HTN 728 8.9 5.1 4.3
No HTN 1,331 6.0 3.7 2.3
RS
All subjects 4,582 6.4 NA NA
HTN 1,433 8.6 NA NA
No HTN 3,149 5.3 NA NA
*defined as the presence of microaneurysms or dot-blot hemorrhages excluding individuals with self-report of diabetes or fasting blood glucose $126 mg/dL
[7.0 mmol/L]) and individuals with secondary causes of retinopathy (e.g. branch or central retinal vein occlusions, late age-related macular degeneration) and other
retinopathy phenotypes including exudates without microaneurysms or dot-blot hemorrhages and pre-retinal or vitreous hemorrhages. RS defined diabetes as a
random glucose .= 11.1 mmol/L, diabetic medication or self-reported history. HTN: Current use of blood pressure medication or systolic/diastolic blood pressure
$140/90. AGES: Age, Gene/Environment Susceptibility-Reykjavik Study. ARIC: Atherosclerosis Risk in Communities study. BMES: Blue Mountains Eye Study. CHS:
Cardiovascular Health Study. MESA: Multi-Ethnic Study of Atherosclerosis. RS: Rotterdam Study. NA: Not Available.
doi:10.1371/journal.pone.0054232.t002
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ratio, and renal function as estimated by serum creatinine
[eGFRcrea]), in the Wellcome Trust Case Control Consortium
[39] (coronary artery disease), the CHARGE Hematology
Working Group (anemia - defined as hemoglobin ,12 g/dl in
women, ,13 g/dl in men) and the Heart and Vascular Health
(HVH) Study [40,41] (stroke and myocardial infarction). Look-ups
in CKDGen were performed in all participants and two
subgroups, those without diabetes and those without hypertension.
Lastly we examined our findings for the SNPs that have
previously been shown to be associated with diabetes or
hypertension in other GWAS [42,43]. We also examined SNPs
associated with diabetic retinopathy in a recently published
candidate gene study [44]. The level of significance was set at
the Bonferroni-corrected p-value for the total number of SNPs
(p,4.861024).
Quantile-quantile (QQ-) plots of –log10 (observed p-value)
versus –log10 (expected p-value) and the Manhattan plots were
generated using R software (http://www.r-project.org). Regional
association and linkage disequilibrium plots were generated using
the SNP Annotation and Proxy Search v2.2 [45]. Forest plots were
generated using Stata Statistical Software: Release 11. College
Station, TX: StataCorp LP. These plots incorporated the I2
heterogeneity statistic to measure the percentage of variation
attributable to differences in effect size between cohorts [46,47].
Results
Population characteristics stratified by hypertension status for
each participating cohort are provided in Table 1. The
distribution of retinopathy and specific lesions (where available)
are provided in Table 2. The primary meta-analysis included all
individuals without diabetes from the six cohorts. There were a
total of 2,675,979 genotyped or imputed SNPs that passed quality
control in one or more cohorts.
No SNPs reached genome wide significance in the primary
analysis adjusted for age, sex, systolic blood pressure and site
specific population stratification covariates (study site or principal
components), Table S1 and Figures S1 and S2.
The secondary analyses were stratified by hypertension status.
Adjustments in the group of participants with hypertension
included age, sex, treatment for hypertension (yes/no) and site
specific population covariates (study site or principal components).
In individuals with hypertension, no SNPs reached genome-wide
significant association, Table S2 and Figures S3 and S4.
The analysis of the group of participants without hypertension
was adjusted for age, sex and site specific population stratification
covariates (study site or principal components), Table S3 and
Figures S5 and S6. One SNP, rs12155400, in the histone
deacetylase 9 gene (HDAC9) on chromosome 7, reached
genome-wide significance, 21.360.23 (beta 6 standard error),
Figure 1. Regional association plot of SNP rs12155400 on chromosome 7 for Caucasians. This figure is the regional association plot of
SNP rs12155400 on chromosome 7 that reached genome-wide significance in the meta-analysis of GWAS results in participants of European ancestry
without diabetes or hypertension. The lead and surrounding SNPs are color coded according to the pair-wise linkage disequilibrium (LD) with the
lead SNP (presented as a diamond) on a scale of r2 from 0 to 1. Estimated recombination rates reflect the local LD structure in the 500 kb buffer
around the index SNP and plotted based on values from HapMap II Centre d’Etude du Polymorphisme Humain collection samples from a Utah (CEU)
population.
doi:10.1371/journal.pone.0054232.g001
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p= 6.661029, Figure 1 and 2. This was an imputed SNP of
relatively low minor allele frequency (MAF) around 2%. The
observed divided by the expected variance for imputed allele
dosage, a measure of imputation quality, was 0.68, 0.64 and 0.70
for AGES, MESA and BMES respectively. Imputation quality in
ARIC and RS was measured by r2 and was 0.71 and 0.74,
respectively.
There were 849 SNPs in the meta-analysis in proximity to the
reference gene HDAC9. Eight of those SNPs were in linkage
disequilibrium (LD) with SNP rs12155400 (r2 ranged from 0.10 to
0.33). Only 1 of those 8 SNPs was genotyped in any cohort,
rs10225230, which was genotyped in ARIC and MESA. The r2
between rs12155400 and rs10225230 was 0.33 and their positions
are separated by 332 K base pairs. The results for the imputed
SNP rs12155400 and the genotyped SNP rs10225230 were exactly
the same in the two cohorts that genotyped rs10225230 with a p-
value of 0.03 and 0.003 for MESA and ARIC respectively,
indicating the results were not due to poor imputation quality at
rs12155400 in these two cohorts. The overall p-value at
rs10225230 was 1.961024. The minor allele frequencies were
similar, 0.02 for rs12155400 and 0.03 for rs10225230.
The SNP with the highest imputation quality that was in LD
with rs12155400 was rs10234685. The imputation quality ranged
from 0.88 to 0.99. The r2 between rs12155400 and rs10234685
was 0.10 and those 2 SNPs were separated by 386,000 base pairs.
Mild retinopathy was not associated with SNP rs10234685, p-
value = 0.20. The minor allele frequency for rs10234685 was 0.07.
We tested the transferability of this SNP and locus (other SNPs
in the HDAC9 gene) in a cohort of Singapore Asian Indians
(SINDI) and a cohort of African Americans in MESA. In both
cases these cohorts were restricted to participants without diabetes
or hypertension. The SNP, rs12155400, did not extend to either
the Singapore Asian Indians (beta = 1.161.23, p = 0.39,
MAF=0.01, n= 1,694) or the African Americans (be-
ta = 0.761.40, p = 0.63, n= 492, MAF=0.01). However, the
power for these studies was around 60% for the Singapore Asian
Indians and less than 10% for the African Americans, Figure S7.
One SNP did reach gene-wide significance (p,4.961024) in the
Singapore Asian Indians, at SNP rs10486302 (p = 3.361024),
Figure 3. In addition, two other SNPs at this locus in linkage
disequilibrium with rs10486302 just missed reaching gene-wide
significance, rs723296 (p= 6.261024, r2 = 0.79) an imputed SNP
and rs12374816 (p = 8.261024, r2 = 0.72) a genotyped SNP. SNP
rs12155400 and rs10486302 are not in linkage disequilibrium but
they do lie within the confines of the same recombination hotspots.
In African Americans, a locus of 3 imputed SNPs reached gene-
wide significance (p,1.761024) around SNP rs213276
(p = 5.261025), Figure 4. The two other SNPs in linkage
Figure 2. Forest plot. This figure display the direction, effect, 95% confidence interval, sample size and % weight from each individual discovery
cohort and overall for the association between SNP rs12155400 on chromosome 7 and retinopathy defined as the presence of microaneurysms or
dot-blot hemorrhages. The I2 heterogeneity statistic is a measure of the percentage of variation attributable to differences in effect sizes between
cohorts. Results from this SNP were not available in CHS.
doi:10.1371/journal.pone.0054232.g002
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disequilibrium included rs213274 (p= 5.561025) and rs213273
(p = 5.861025). These SNPs lie in the zone adjacent to the
recombination hotspots shared by the other two ethnic groups.
In silico look-ups of the association between SNP rs12155400
and several micro- and macrovascular diseases were done and
the results are shown in Table 3. In participants without
hypertension in the CKDGen consortium, the SNP was
marginally associated with microalbuminuria and chronic kidney
disease (p = 0.02 and 0.04 respectively) before correcting for
multiple testing but was not associated with the urinary
albumin/creatinine ratio or renal function estimated by serum
creatinine. The small minor allele frequency prevented testing in
the Heart and Vascular Health Study. There was no association
between this SNP and coronary artery disease in the Wellcome
Trust Case Control Consortium or with anemia in the
CHARGE Hematology Working Group.
We examined our findings in a set of SNPs that have previously
been shown to be associated with diabetes or hypertension in other
GWAS studies and two SNPs associated with diabetic retinopathy
in a recently published candidate gene study. None of these SNPs
were associated with retinopathy (p,4.861024) in the primary
analytical group or either subgroup stratified by hypertension
status, Tables S4, S5 and S6.
Discussion
Results of our primary analysis and secondary analysis of
individuals with hypertension showed no evidence of a genetic
association with mild retinopathy. One SNP, rs12155400, reached
genome-wide significant association with mild retinopathy in
individuals of European ancestry without diabetes and hyperten-
sion, in the histone deacetylase 9 gene (HDAC9) gene on
chromosome 7. The available evidence suggests this is a false
positive finding. The SNP is located in an intronic region. The
minor allele frequency was low, less than 2%. The SNP was
imputed and the quality of the imputation was modest at best with
an r2 of about 0.7. There were no other common variants in the
HDAC9 gene associated with the outcome. The SNP findings did
not extend to a cohort of Singapore Asian Indians or African
Americans although there was limited power to detect an
association in these smaller cohorts.
Diabetes and hypertension are the primary risk factors for
retinopathy [22,23] but the etiology of mild retinopathy in
individuals without diabetes remains unclear [4]. Determining
these risk factors may shed light on the association between mild
retinopathy and other conditions such as renal dysfunction
[10,11,12], incident hypertension [1], clinical stroke
Figure 3. Regional association plot of SNP rs10486302 on chromosome 7 for Singapore Asian Indians. This figure is the regional
association plot of SNP rs10486302 on chromosome 7 that reached gene-wide significance (p,4.961024) in the testing of transferability of the
discovery SNP, rs12155400, to other SNPs in the histone deacetylase 9 gene in a cohort of Singapore Asian Indians without diabetes or hypertension.
The lead and surrounding SNPs are color coded according to the pair-wise linkage disequilibrium (LD) with the lead SNP (presented as a diamond) on
a scale of r2 from 0 to 1. Estimated recombination rates reflect the local LD structure in the 500kb buffer around the index SNP and plotted based on
values from HapMap II Han Chinese of Beijing China (HCT)/Japanese in Tokyo, Japan (JPT) populations.
doi:10.1371/journal.pone.0054232.g003
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[13,14,15,16,17], congestive heart failure [18], cardiovascular
mortality [19,20] and risk of clinical diabetes [21].
Common genetic factors are thought to underlie the pathogen-
esis of microvascular disease in the eye and kidney, particularly in
persons without the major risk factors for pathologies in these
organs; diabetes and hypertension. There are congenital syn-
dromes associated with genetic defects affecting both the retinal
and renal vasculature such as von Hippel Lindau Disease and
Sturge-Weber-Krabble Syndrome [48].
We found a number of SNPs in our study with highly suggestive
p-values (p,9.99E206) some of which are associated with retinal
degenerations. For example, in the primary analysis there were
two SNPs associated with mild retinopathy, rs7553035 and
rs21661074 near RD3 on chromosome 1. This gene encodes a
retinal protein that is associated with promyelocytic leukemia-gene
product bodies in the nucleus. Mutations in this gene cause Leber’s
congenital amaurosis type 12 [49]. Another locus of interest in the
secondary analysis of subjects with hypertension included SNPs
near TEAD1 on chromosome 11, a gene associated with
peripapillary chorioretinal degeneration [50]. In this same group,
SNP rs1933752 near the UTRN gene on chromosome 6 was also
associated mild retinopathy. The protein encoded by this gene
shares both structural and functional similarities with the
dystrophin gene. Dystrophins are normally part of critical
cytoskeleton-associated membrane-bound molecular scaffolds in-
volved in blood-brain barrier function [51].
The negative results from our study do not completely rule out
genetic effects in the development of mild retinopathy. Limitations
in our study make finding these associations difficult. The
combined phenotype of microaneurysms or dot-blot hemorrhages
is transitory in nature [2]. Photos in each of these studies were
taken with a limited number of fields and sometimes only in one
eye. There are potentially many pathways to develop both dot-blot
hemorrhages and microaneurysms some of which may be unique
to each phenotype. All of these limitations lead to misclassifications
that tend to bias results towards the null.
Despite the lack of genome-wide significant findings, this study
does represent the first large scale genetic study of mild
retinopathy in a population based cohort. This work serves to
highlight some of the difficulties in studying this phenotype
particularly using cross sectional retinal observations. Hopefully it
will provide insights for better research methods in the future as
well as serve as a resource for candidate gene analyses of some of
our highly suggestive hits in biologically relevant genes or
rs12155400 in HDAC9. HDAC9 has recently been reported to be
associated with large vessel ischemic stroke [52] and there was
evidence of locus transferability to other SNPs in HDAC9 that
reached gene-wide significance in Asians and African Americans.
Figure 4. Regional association plot of SNP rs213276 on chromosome 7 for African Americans. This figure is the regional association plot
of SNP rs213276 on chromosome 7 that reached gene-wide significance (p,5.261025) in the testing of transferability of the discovery SNP,
rs12155400, to other SNPs in the histone deacetylase 9 gene in a cohort of African Americans without diabetes or hypertension. The lead and
surrounding SNPs are color coded according to the pair-wise linkage disequilibrium (LD) with the lead SNP (presented as a diamond) on a scale of r2
from 0 to 1. Estimated recombination rates reflect the local LD structure in the 500 kb buffer around the index SNP and plotted based on values from
HapMap II Yoruba in Ibadan, Nigeria (YRI) population.
doi:10.1371/journal.pone.0054232.g004
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In conclusion, results from this study showed little evidence that
the presence of mild retinopathy in individuals without diabetes
was associated with SNPs. Further studies are needed to explore
the remaining highly suggestive SNPs. This may include fine
mapping in HDAC9, gene-environment interaction studies or
pathway analyses. Identifying genes associated with these signs
may help unravel novel pathways and determinants of microvas-
cular diseases.
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